Market Overview

Stifel Nicolaus Initiates Biotie Therapies At Buy


Analysts at Stifel Nicolaus initiated coverage on Biotie Therapies Oyj (ADR) (NASDAQ: BITI) with a Buy rating.

The target price for Biotie Therapies is set to $30.

Biotie Therapies' shares rose 4.02 percent to $19.13 in pre-market trading.

Latest Ratings for BITI

Apr 2016Roth CapitalTerminatesNeutral
Mar 2016RBC CapitalDowngradesOutperformSector Perform
Jul 2015Roth CapitalInitiates Coverage onBuy

View More Analyst Ratings for BITI
View the Latest Analyst Ratings


Related Articles (BITI)

View Comments and Join the Discussion!

Posted-In: Stifel NicolausInitiation Analyst Ratings

Latest Ratings

IBIOCantor FitzgeraldInitiates Coverage On3.0
UPLDCanaccord GenuityMaintains57.0
EJefferiesInitiates Coverage On
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at